Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Groove Biopharma (Seattle, WA) a development-stage biopharmaceutical company focused on microRNA therapeutics for cancer, fibrosis and infectious disease, closed a $6M Series B financing. Participants include Amgen Ventures, Versant Ventures, Alexandria Real Estate Equities, ARCH Venture Partners, OVP Venture Partners and WRF Capital.

HTG (Tuscon, AZ) a commercial-stage molecular technology company focused on gene expression profiling, miRNA and mRNA measurement, translational medicine and diagnostic applications, closed a $15.7M Series D financing. Participants include Novo Ventures, Fletcher Spaght Ventures, Merck Capital Ventures, Solstice Capital and Valley Ventures.

Sistemic (Scotland) a development-stage biopharma focused on miRNA expression profiling, closed a $1M series A financing. Participants include ChimeraBio and Scottish Enterprise Co-Investment Fund.

miRagen Therapeutics (Boulder, CO) a preclinical-stage biopharmaceutical company focused on the development of miRNA therapeutics for cardiovascular and muscle diseases, closed a $4 Series B, bringing the total round financing to $12M. Participants include Boulder Ventures, Amgen Ventures, Broadview Ventures, The Peierls Foundation and Atlas Venture.

Miragen (Boulder, CO) development-stage company focused on the treatment of cardiovascular and muscle disease based on microRNA biology, closed a $8M Series A financing. Participants include Atlas Venture and Boulder Ventures.


to top of page...